Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, adult, Lymphomas, non-Hodgkin lymphoma, elderly, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, B Cell lymphoma, Clinical Research, health outcomes research, Diseases, Therapies, aggressive lymphoma, therapy sequence, real-world evidence, Lymphoid Malignancies, registries, Technology and Procedures, Study Population, Human, imaging, Minimal Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, adult, Lymphomas, non-Hodgkin lymphoma, elderly, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, B Cell lymphoma, Clinical Research, health outcomes research, Diseases, Therapies, aggressive lymphoma, therapy sequence, real-world evidence, Lymphoid Malignancies, registries, Technology and Procedures, Study Population, Human, imaging, Minimal Residual Disease
Monday, December 12, 2022: 10:30 AM-12:00 PM
393-396
(Ernest N. Morial Convention Center)
Moderators:
Michael D. Jain, MD, PhD, Moffitt Cancer Center
and
Olalekan O. Oluwole, MBBS, Vanderbilt Univeristy
Disclosures:
Oluwole: Kite, a Gilead Company: Research Funding; Janssen: Consultancy; Novartis: Consultancy; Pfizer: Consultancy; TG Therapeutics: Consultancy; Curio Science: Consultancy; ADC Therapeutics: Consultancy; Nektar: Consultancy; Syncopation: Consultancy; Epizyme: Consultancy.
10:30 AM
10:45 AM
11:00 AM
11:15 AM
11:30 AM
11:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH